Recent Cases
6 May 2010 - Cytos Biotechnology Ltd sells platform technology for the identification of monoclonal antibodies
Cytos Biotechnology Ltd, a public Swiss biotechnology company specializing in the discovery, development and commercialization of Immunodrugs, announced the sale of its platform technology for the identification of monoclonal antibodies to Intercell AG. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.
Bär & Karrer acts as legal counsel of Cytos Biotechnology Ltd. The team includes Michael Trippel (M&A), Markus Wang (IP) and Thomas Rohde (M&A).